Timing of hormone therapy use impacts alzheimer's risk

October 25, 2012
Timing of hormone therapy use impacts alzheimer's risk
Use of hormone therapy within five years of menopause is associated with a reduction in the risk of Alzheimer's disease, according to a study published online Oct. 24 in Neurology.

(HealthDay)—Use of hormone therapy (HT) within five years of menopause is associated with a reduction in the risk of Alzheimer's disease (AD), according to a study published online Oct. 24 in Neurology.

Huibo Shao, from Weill Cornell Medical College in New York City, and colleagues examined whether the timing or type of HT impacts its association with AD. A cohort of 1,768 women from the Cache County Study who provided a detailed history of age at and use of HT were followed between 1995 and 2006. One hundred seventy-six women developed incident AD during this period.

The researchers found that use of any type of HT within five years of menopause was associated with a significant 30 percent reduction in the risk of AD, particularly if HT was used for 10 years or more. There was no reduction in AD risk seen for women who initiated HT five years or more after menopause. who began "opposed" estrogen-progestin compounds within three years preceding the Cache County Study baseline had an increased risk of AD (adjusted hazard ratio, 1.93; 95 percent confidence interval, 0.94 to 3.96), which was similar to that reported in randomized trial participants assigned to opposed HT.

"Association of HT use and risk of AD may depend on timing of use. Although possibly beneficial if taken during a critical window near menopause, HT (especially opposed compounds) initiated in later life may be associated with increased risk," the authors write. "The relation of AD risk to timing and type of HT deserves further study."

Explore further: VTE risk varies by hormone therapy formulation

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

VTE risk varies by hormone therapy formulation

September 18, 2012
(HealthDay)—The risk of venous thromboembolism (VTE) in postmenopausal women differs considerably according to the formulation of hormone therapy (HT) used, with the highest VTE risk seen in users of oral estrogen-progestin ...

Long-term use of estrogen hormone therapy linked to higher risk for breast cancer

April 2, 2012
In a landmark study, researchers have linked the long-term use of estrogen plus progesterone and estrogen-only hormone therapy with a higher risk for developing breast cancer.

The Women's Health Initiative: An unforgettable decade

May 31, 2012
The 10-year anniversary of the historic Women's Health Initiative (WHI) Hormone Therapy Trial report, which radically changed the practice of women's health, will be commemorated in July 2012. In anticipation of this event, ...

The Women's Health Initiative study and hormone therapy -- what have we learned 10 years on?

May 22, 2012
In July 2002 the publication of the first Women's Health Initiative (WHI) report caused a dramatic drop in Menopausal Hormone Therapy (HT ) use throughout the world. Now a major reappraisal by international experts, published ...

Drop in hormone therapy use linked with drop in mammogram rates

August 22, 2011
A new analysis has found that a decline in hormone therapy (HT) use among women aged 50 to 64 years is linked with lower mammogram rates among these women. Published early online in Cancer, a peer-reviewed journal of the ...

Recommended for you

Anxiety: An early indicator of Alzheimer's disease?

January 12, 2018
A new study suggests an association between elevated amyloid beta levels and the worsening of anxiety symptoms. The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of ...

One of the most promising drugs for Alzheimer's disease fails in clinical trials

January 11, 2018
To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer's disease and come up short, we can now add three more.

Different disease types associated with distinct amyloid-beta prion strains found in Alzheimer's patients

January 9, 2018
An international team of researchers has found different disease type associations with distinct amyloid-beta prion strains in the brains of dead Alzheimer's patients. In their paper published in Proceedings of the National ...

Advances in brain imaging settle debate over spread of key protein in Alzheimer's

January 5, 2018
Recent advances in brain imaging have enabled scientists to show for the first time that a key protein which causes nerve cell death spreads throughout the brain in Alzheimer's disease - and hence that blocking its spread ...

Molecular mechanism behind HIV-associated dementia revealed

January 5, 2018
For the first time, scientists have identified and inhibited a molecular process that can lead to neurodegeneration in patients with HIV, according to a Northwestern Medicine study published in Nature Communications.

Mice with frequent flier miles advance the Alzheimer's cause

January 4, 2018
Alzheimer's disease wreaks emotional havoc on patients, who are robbed of their memories, their dignity, and their lives. It's financially devastating as well: care for Alzheimer's patients is predicted to top $1 trillion ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.